Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) announced on May 4, 2022, that its board's compensation committee granted stock options and restricted stock units (RSUs) to 23 newly-hired employees. The total granted includes options for 138,100 shares and RSUs for 69,050 shares, with an exercise price of $9.29 per share, equivalent to the stock's closing price on the grant date. These options and RSUs will vest over four years, contingent on continued employment, and are compliant with Nasdaq Listing Rule 5635(c)(4).

BioCryst Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted BCX9250 access to its Priority Medicines (PRIME) scheme, making it the first investigational drug for fibrodysplasia ossificans progressiva (FOP) eligible for this program. The PRIME initiative aims to expedite the development of medicines addressing unmet medical needs through enhanced interaction with developers. BCX9250, an oral ALK-2 inhibitor, has shown promising safety and tolerability in Phase 1 trials, indicating potential for once-daily dosing.

BioCryst Pharmaceuticals (BCRX) will announce its Q1 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss these results and provide corporate updates. Interested parties can join the call via telephone or access it through a live webcast from the company's investor relations page. BioCryst focuses on developing oral treatments for rare diseases, with products like ORLADEYO approved in multiple countries and ongoing programs for other novel therapies. For more details, visit www.biocryst.com.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 11:45 a.m. ET. A live audio webcast and replay will be accessible in the Investors & Media section of BioCryst’s website. The company focuses on discovering novel oral medicines for rare diseases, with products like ORLADEYO® approved in multiple regions. BioCryst also has ongoing programs for complement-mediated diseases and viral infections.

BioCryst Pharmaceuticals (BCRX) has announced a pause in the enrollment of new patients in its clinical trials for BCX9930 due to elevated serum creatinine levels observed in some participants. This affects the REDEEM-1, REDEEM-2, and RENEW trials, although current participants will continue their treatment. The company is investigating these safety concerns before proceeding further. BioCryst develops medicines for rare diseases and continues to progress with other drugs in its pipeline.

BioCryst Pharmaceuticals (BCRX) granted stock options and restricted stock units (RSUs) to 19 newly-hired employees on March 31, 2022. The total stock options cover 124,800 shares and RSUs cover 47,400 shares, with an exercise price of $16.26 per share, equivalent to the closing stock price on the grant date. The options and RSUs vest annually over four years, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with BioCryst’s Inducement Equity Incentive Plan.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in upcoming healthcare conferences. The company will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. ET and at the Barclays Global Healthcare Conference in Miami Beach, Florida, on March 16, 2022, at 2:35 p.m. ET. Both presentations will be available via live audio webcast on BioCryst's website. The company focuses on developing innovative treatments for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 17 new employees, totaling 290,000 shares. The options have an exercise price of $16.61, aligned with the closing stock price on February 28, 2022. These grants aim to attract talent as part of Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, contingent on continued employment. BioCryst specializes in oral treatments for rare diseases and continues to advance its product pipeline including ORLADEYO and BCX9930.

BioCryst Pharmaceuticals (BCRX) announced promising long-term efficacy and safety results from the APeX-2 trial of ORLADEYO (berotralstat), aimed at treating hereditary angioedema (HAE). Data presented at the 2022 AAAAI annual meeting revealed that patients had a remarkable average of 94 percent attack-free days over 96 weeks. The study involved 121 patients, showing sustained attack rate reductions across various groups. ORLADEYO was well-tolerated, with no serious adverse events, suggesting its potential as an effective prophylactic therapy.